Today: 19 March 2026
Subscribe
Browse Category

EPA:TEP 23 October 2025 - 7 December 2025

CAC 40 and World Indices Weekly Snapshot: Fed Cut Bets, Flat Paris Trade and a Cautiously Optimistic Global Rally (5–7 December 2025)

CAC 40 and World Indices Weekly Snapshot: Fed Cut Bets, Flat Paris Trade and a Cautiously Optimistic Global Rally (5–7 December 2025)

The CAC 40 closed Friday, 5 December at 8,114.74, down 0.09% for the day and flat for the week, as French equities saw little movement ahead of a key Federal Reserve meeting. None of the week’s sessions moved more than 0.4%. Select stocks like Saint-Gobain and Edenred rose nearly 3%, while losses in oil, utilities, and financials offset gains. U.S. and European indices posted modest weekly gains.
7 December 2025
···
South Africa’s Outsourcing Boom Becomes a New ‘Gold Rush’ for Jobs and Investment

South Africa’s Outsourcing Boom Becomes a New ‘Gold Rush’ for Jobs and Investment

South Africa’s BPO sector now generates about 35 billion rand ($2 billion) a year and employs over 70,000 in the Western Cape, up from fewer than 2,000 offshore jobs 15 years ago. UK and European firms, drawn by lower costs and skilled English-speaking workers, are expanding operations in Cape Town, where nearly 100,000 call-centre staff serve global clients. Connectivity and education gaps threaten to limit growth outside major cities.
23 October 2025
·

Stock Market Today

  • Soligenix Publishes HyBryte Clinical Data Validating Safety and Efficacy
    March 19, 2026, 2:04 PM EDT. Soligenix (NASDAQ: SNGX), a biopharmaceutical firm targeting rare diseases, reported the publication of clinical trial data on HyBryte (synthetic hypericin) in the peer-reviewed journal Expert Opinion on Investigational Drugs. The summary underscores HyBryte's safety profile, non-mutagenic mechanism, and demonstrated efficacy against cutaneous T-cell lymphoma (CTCL). The data supports HyBryte's potential as a first-line treatment. Soligenix continues its ongoing FLASH2 Phase 3 trial for HyBryte, with an interim analysis slated for Q2 2026. The company focuses on rare disease therapies and vaccine programs underpinned by proprietary technology. This publication bolsters investor confidence as Soligenix advances regulatory efforts toward global commercialization of HyBryte, expanding its pipeline across inflammatory and infectious diseases.
Go toTop